🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Phreesia executive sells over $100k in company stock

Published 2024-04-10, 05:24 p/m
PHR
-

Phreesia, Inc. (NYSE:PHR) has reported that its Principal Accounting Officer, Janet Gunzburg, sold a total of $104,218 worth of company stock, according to a recent SEC filing. The transactions occurred over a series of sales with prices ranging from $22.6161 to $23.2733 per share.

The filings show that Gunzburg sold 2,817 shares on March 19, 2024, at a weighted average price of $23.2733, and an additional 1,709 shares on April 8, 2024, in two separate transactions at weighted average prices of $22.6161 and $23.0163. The sales were part of a mandatory sell-to-cover policy by Phreesia to satisfy tax withholding obligations related to the settlement of restricted stock units.

Gunzburg's transactions were disclosed late due to an administrative error, as noted in the footnotes of the filing. Despite the sales, the filings indicate that Gunzburg still holds a substantial number of shares in the company, with 38,900 shares remaining after the reported transactions.

Phreesia, Inc. specializes in healthcare software solutions, providing a platform for patient intake management and other services. The company's stock trades on the New York Stock Exchange under the ticker symbol NYSE:PHR.

Investors and stakeholders of Phreesia, Inc. often monitor insider transactions as they can provide insights into executives' confidence in the company's current standing and future prospects. The recent sales by a high-ranking officer such as Gunzburg will likely be of interest to the market, providing additional context for the company’s stock performance.

InvestingPro Insights

Amidst the news of insider transactions at Phreesia, Inc. (NYSE:PHR), current metrics from InvestingPro show a mixed financial landscape for the company. With a market capitalization of $1.31 billion, Phreesia's financial position is significant in the healthcare software industry. The company's revenue growth is notable, with a 26.84% increase in the last twelve months as of Q4 2024, indicating a strong demand for its patient intake management solutions. Despite this growth, Phreesia operates with a moderate level of debt, as per an InvestingPro Tip, which suggests that the company is managing its leverage carefully.

The P/E ratio stands at -9.20, reflecting market sentiment that the company may face challenges in achieving profitability in the near term. This aligns with another InvestingPro Tip indicating that analysts do not expect Phreesia to be profitable this year. The company's stock performance also presents a varied picture, with a 21.24% increase over the past six months, yet a year-to-date return of -1.12% and a 1-year price total return of -24.08%.

InvestingPro also highlights that Phreesia does not pay dividends, which may influence investment decisions for those seeking regular income from their stock holdings. For investors interested in a deeper analysis, there are additional InvestingPro Tips available, which can be accessed with the coupon code PRONEWS24 for an extra 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.